Current Usefulness of Intrapartum AZT for Perinatal HIV Transmission Prevention
The French Perinatal Cohort study looked at women delivering between 1997-2010 to detemine the usefulness of intrapartum AZT when a mother receives HAART during pregnancy. Usage of intrapartum AZT was over 95%. Lack of intrapartum AZT was associated with older age, multiparity, and preterm and vaginal delivery. Overall transmission rates were higher in women with higher viral loads at delivery. Researchers concluded that IV AZT during labor is useful in prevention of mother-to-child transmission but felt for those women without mitigating factors and with low viral loads at delivery, systematic use of IV AZT is unnecessary.
Citation:
Briand N, Warszawski J, Mandelbrot L, Dollfus C, Pannier E, Cravello L, Nguyen R, Matheron I, Winer N, Tubiana R, Rouzioux C, Faye A, Blanche S; ANRS-EPF CO1-CO11 Study Group. Is intrapartum intravenous zidovudine for prevention of mother-to-child HIV-1 transmission still useful in the combination antiretroviral therapy era? Clin Infect Dis. 2013 Sep;57(6):903-14.
Original Article (subscription may be required)
